More Company News

Arecor Therapeutics

FY22 results
16 Mar 2023Read More

Arecor Therapeutics

Statement re: Jounce Therapeutics press release
15 Mar 2023Read More

Arecor Therapeutics

Closing of fruquintinib licence to Takeda outside China
14 Mar 2023Read More

Arecor Therapeutics

MED3000 commercial and US regulatory update
14 Mar 2023Read More

Arecor Therapeutics

RXC004 topline data from a Phase II monotherapy module
08 Mar 2023Read More

Arecor Therapeutics

Preliminary Q422 & FY22 revenue
07 Mar 2023Read More

Arecor Therapeutics

FY22 results
28 Feb 2023Read More

Arecor Therapeutics

Completion of enrolment in amidizalisib China Phase II registration trial in FL
27 Feb 2023Read More

Arecor Therapeutics

Recommended business combination with Jounce Therapeutics
23 Feb 2023Read More

Arecor Therapeutics

Encouraging early efficacy data from ModiFY trial
21 Feb 2023Read More

1 2 3 4 … 56
Return to Arecor Therapeutics
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).